» Articles » PMID: 24512928

Work Schedule, Sleep Duration, Insomnia, and Risk of Fatal Prostate Cancer

Overview
Journal Am J Prev Med
Specialty Public Health
Date 2014 Feb 12
PMID 24512928
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Studies of breast cancer in women and laboratory studies provide evidence that shift work involving circadian rhythm disruption is a probable human carcinogen. However, evidence linking shift work and other circadian disruption factors to prostate cancer risk is limited.

Purpose: To examine associations of work schedule (i.e., rotating shift work, fixed night and fixed afternoon/evening shift work); sleep duration; and insomnia frequency with prostate cancer mortality.

Methods: The Cancer Prevention Study-II is a large prospective cohort study of U.S. adults. Work schedule, sleep duration, insomnia frequency, and other information was self-reported in 1982. Among 305,057 employed men, aged ≥29 years who were cancer free at baseline, there were 4974 prostate cancer deaths during follow-up through 2010. In 2013, multivariable-adjusted relative risks (RRs) and 95% CIs were computed using Cox proportional hazards regression.

Results: Work schedule and insomnia frequency were not associated with risk of fatal prostate cancer. Short sleep duration was associated with higher risk of prostate cancer during the first 8 years of follow-up, compared to 7 hours/night, the RRs (95% CIs) for 3-5 and 6 hours/night were 1.64 (1.06, 2.54), and 1.28 (0.98, 1.67), respectively. There was no association between sleep duration and fatal prostate cancer during later follow-up.

Conclusions: These results do not support associations of work schedule or insomnia frequency with prostate cancer mortality. The association between short sleep duration and higher risk of fatal prostate cancer only during the first 8 years of follow-up suggests that short sleep duration could affect later stages of prostate carcinogenesis.

Citing Articles

Circadian rhythm related genes signature in glioma for drug resistance prediction: a comprehensive analysis integrating transcriptomics and machine learning.

Liao J, Duan Y, Xu X, Liu Y, Zhan C, Xiao G Discov Oncol. 2025; 16(1):119.

PMID: 39909964 PMC: 11799505. DOI: 10.1007/s12672-025-01863-2.


Association of sleep duration and all-cause and cancer-specific mortality: results of 2004 national health interview survey (NHIS).

Biswas P, Adebile T, Sejoro S, Liu M, Zhang X, Tu W Sleep Biol Rhythms. 2025; 23(1):55-65.

PMID: 39801935 PMC: 11717743. DOI: 10.1007/s41105-024-00551-y.


Night shift work and prostate cancer: a large cohort study from UK Biobank and Mendelian randomisation study.

Yang G, Yang Y, Lv K, Wu Y, Song T, Yuan Q BMJ Open. 2024; 14(12):e084401.

PMID: 39725442 PMC: 11683915. DOI: 10.1136/bmjopen-2024-084401.


Sleep and cancer mortality in the Cancer Prevention Study-II.

Donzella S, Deubler E, Patel A, Phipps A, Zhong C Cancer Causes Control. 2024; 35(12):1541-1555.

PMID: 39240291 DOI: 10.1007/s10552-024-01910-3.


The SMILE scale: a wellness behavioral tool for patients with cancer.

Vater L, Ajrouch A, Monahan P, Jennewein L, Han Y, Karkash A Qual Life Res. 2024; 33(12):3401-3408.

PMID: 39230840 DOI: 10.1007/s11136-024-03781-2.